Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations-Reference-Cited by-同舟云学术

Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations

Published:2024-09-11 Issue: Volume: Page:
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wei Tian-Hua¹,Wang Zi-Xuan¹,Lu Meng-Yi²,Xu Yu-Jing¹,Yang Jin¹,Ni Xing-Feng¹,Cheng Yang¹,Zhang Meng-Yuan¹,Liu Jia-Chuan¹,Li Qing-Qing¹,Cai Jiao¹,Chen Zi-Jun¹,Kang Ji-Bo¹,Li Nan¹,Dai Wei-Chen¹,Ding Ning¹,Yu Yan-Cheng¹^ORCID,Leng Xue-Jiao¹,Xue Xin¹^ORCID,Wang Xiao-Long¹^ORCID,Sun Shan-Liang¹,Yang Ye³,Li Nian-Guang¹^ORCID,Shi Zhi-Hao⁴

Affiliation:

1. National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, Jiangsu 210023, China

2. Department of Biostatistics, School of Public Health, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu 211166, China

3. School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China

4. Laboratory of Molecular Design and Drug Discovery, School of Science, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, Jiangsu 211198, China

Funder

National Key Research and Development Program of China

National Natural Science Foundation of China

Priority Academic Program Development of Jiangsu Higher Education Institutions

Natural Science Foundation of Jiangsu Provincial Colleges and Universities

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00529

Reference35 articles.

1. Emerging agents and regimens for AML

2. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal

3. Targeting FLT3 mutations in AML: review of current knowledge and evidence

4. A review of FLT3 inhibitors in acute myeloid leukemia

5. Potential targeting of FLT3 acute myeloid leukemia